31 July 2018
Visiongain has launched a new pharma report Global OTC Pharmaceutical Market Forecast 2018-2028: Forecasts by Product (Cough, Cold and Allergy, Analgesics, Gastrointestinal, Dermatology, Eye Care, Smoking Cessation Aids, Others) and Geography, with Analysis of Leading Companies
The potential of the OTC pharmaceutical market remains significant and it is a growing segment in the largely stagnant overall pharmaceutical market. In the face of looming patent expiry and falling R&D productivity, the consumer healthcare and OTC business offers distinct advantages to pharmaceutical companies looking to create a diverse portfolio of businesses that achieves sustained revenue growth over the next ten years.
The lead analyst of the report commented “The growth of the OTC Pharmaceutical market will be driven by ageing demographics, cost pressures on healthcare providers, liberalisation of regulatory requirements, shifting cultural practices towards self-medication, and the continued switching of drugs from prescription-only to OTC.
Competition from private-label brands, regulatory concerns over OTC switching and the effective marketing of products via the Internet and social media are some of the challenges that OTC manufacturers and brands will need to address in the future.”
Leading companies featured in the report include Bayer AG, GlaxoSmithKline (GSK) Consumer Care, Perrigo Company PLC, Johnson & Johnson, Daiichi Sankyo Co., Ltd, Pfizer Inc., Procter & Gamble, Sanofi S.A, Reckitt Benckiser Group PLC, Cipla, Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.